Organon and Co
organon.comTotal trials
505
Active
2
Phase 3
297
Total enrollment
1,737,417
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| tapinarof cream, 1% | — | — | — | — | 8 | ||
| Vehicle Cream | — | — | — | — | — | 5 |
Next readouts
- 2026-10
- 2028-01
Top conditions
- Hypercholesterolemia85
- Asthma55
- Seasonal Allergic Rhinitis25
- Hypertension23
- Contraception23
- Schizophrenia19
- Allergic Rhinitis15
- Atherosclerosis12
Frequently asked questions about Organon and Co
- How many clinical trials does Organon and Co have on ClinicalTrials.gov?
- Organon and Co is listed as the lead sponsor on 505 clinical trials in ClinicalTrials.gov, 2 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Organon and Co's trials are in Phase 3?
- 297 of Organon and Co's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Organon and Co focus on?
- Organon and Co's most-studied conditions on ClinicalTrials.gov are Hypercholesterolemia, Asthma, Seasonal Allergic Rhinitis, Hypertension, Contraception.
- When are Organon and Co's next clinical trial readouts?
- Organon and Co has 2 upcoming primary-completion readouts tracked here; the soonest is “Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects”, expected around 2026-10.